Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top stocks to buy in Michael Burry’s stock portfolio. On October 6, the company announced it is poised to incur an $83 million in-process research and development (IPR&D) charge.
Copyright: nexusplexus / 123RF Stock Photo
The charge is related to an $80 million up-front payment made to Hansoh Pharmaceuticals Group Company Limited as part of a 2025 license agreement. In addition to up-front, opt-in, and some development milestone payments, acquired IPR&D charges may also include milestone payments and premiums paid on equity securities associated with licensing and partnership agreements.
The charge is expected to reduce the company’s GAAP and non-GAAP net income per diluted share by about $0.68 in the third quarter.
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious and rare diseases, including eye diseases, cancer, neurological conditions, inflammatory and allergic diseases, and cardiovascular diseases.
READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.
This article is originally published at Insider Monkey.
